We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

225 hedge funds and large institutions have $3.27B invested in Neurocrine Biosciences in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 97 increasing their positions, 75 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

97.13% more ownership

Funds ownership: 0% → 97.13% (+97%)

29% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 75

6% less call options, than puts

Call options by funds: $23.6M | Put options by funds: $25.1M

8% less funds holding

Funds holding: 244 → 225 (-19)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

24% less capital invested

Capital invested by funds: $4.32B → $3.27B (-$1.05B)

37% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 41

Holders
225
Holders Change
-19
Holders Change %
-7.79%
% of All Funds
5.63%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
26
Increased
97
Reduced
75
Closed
41
Calls
$23.6M
Puts
$25.1M
Net Calls
-$1.48M
Net Calls Change
-$32.7M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.6M
2
HM
HealthCor Management
New York
+$44.8M
3
PA
Perceptive Advisors
New York
+$38M
4
Franklin Resources
Franklin Resources
California
+$18M
5
GPP
Great Point Partners
Connecticut
+$16.1M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$153M
2
EAM
Eagle Asset Management
Florida
-$46.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$35.2M
4
American Century Companies
American Century Companies
Missouri
-$25.8M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
DILIC
151
Dai-ichi Life Insurance Company
Japan
$645K +$755K +16,677 New
WC
152
Woodstock Corp
Massachusetts
$642K -$153K -3,381 -17%
URS
153
Utah Retirement Systems
Utah
$608K +$4.53K +100 +0.6%
AB
154
Amalgamated Bank
New York
$593K +$71.7K +1,585 +12%
SAM
155
Shell Asset Management
Netherlands
$591K – – –
HI
156
Handelsinvest Investeringsforvaltning
Denmark
$569K – – –
DCM
157
Dupont Capital Management
Delaware
$568K +$567K +12,528 +582%
Nomura Asset Management
158
Nomura Asset Management
Japan
$565K – – –
Lazard Asset Management
159
Lazard Asset Management
New York
$549K -$1.56M -34,443 -71%
TCM
160
Traynor Capital Management
Pennsylvania
$537K -$94.7K -2,092 -14%
N
161
Nuveen
North Carolina
$530K – – –
RJA
162
Raymond James & Associates
Florida
$528K -$266K -5,881 -30%
PAM
163
Paradigm Asset Management
New York
$515K -$18.1K -400 -3%
BNP Paribas Financial Markets
164
BNP Paribas Financial Markets
France
$494K -$76.8K -1,697 -12%
Canada Pension Plan Investment Board
165
Canada Pension Plan Investment Board
Ontario, Canada
$453K +$109K +2,400 +26%
DTL
166
Dynamic Technology Lab
Singapore
$449K +$135K +2,991 +35%
ECM
167
Endurant Capital Management
California
$445K -$31.7K -700 -6%
HI
168
HBK Investments
Texas
$437K +$512K +11,300 New
LCM
169
Landscape Capital Management
New Jersey
$423K +$495K +10,940 New
Canada Life
170
Canada Life
Manitoba, Canada
$399K – – –
SAMH
171
Shanda Asset Management Holdings
British Virgin Islands
$387K – – –
Legal & General Group
172
Legal & General Group
United Kingdom
$362K +$51.4K +1,136 +14%
JG
173
Jefferies Group
New York
$357K -$203K -4,494 -33%
Nomura Holdings
174
Nomura Holdings
Japan
$350K -$1.76K -39 -0.4%
VFA
175
Virtus Fund Advisers
Connecticut
$345K -$138K -3,059 -26%
5 6
7
8 9

NBIX Hedge Fund Activity: Q4 2016 in Review

225 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2016, worth a combined $3.27B — down 24% from $4.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of NBIX and 26 opened new positions — a net loss of 15 holders — while 75 trimmed existing stakes and 97 added.

The largest buyer was Millennium Management, adding an estimated $55.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $153M.

  • 225 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2016, down from 244 in Q3 2016.
  • Funds reported $3.27B of Neurocrine Biosciences stock for Q4 2016, down 24% quarter-over-quarter.
  • 26 funds opened new Neurocrine Biosciences positions in Q4 2016 and 41 closed out, a net change of -15 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2016 was Millennium Management, an estimated $55.6M added.
  • The largest Neurocrine Biosciences seller in Q4 2016 was T. Rowe Price Associates, an estimated $153M sold.

Based on aggregated 13F filings for Q4 2016.